Citigroup: Gives ALI HEALTH (00241) a "buy" rating with a target price of HK $9.5.

Citigroup released a research report stating that Ali Health (00241) had a 10% year-on-year increase in revenue to 14.3 billion RMB in the first half of the 2025 fiscal year, lower than the bank's expectations. Net profit was 769 million RMB, up 73% year-on-year, exceeding the bank's expectations. The gross profit margin increased from 22.1% in the same period last year to 24.8% in the current period, with sales and administrative expenses slightly increasing to 8.2%. The bank set a target price of HK$9.5 for the company, with a "buy" rating.